Cargando…
Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex
Background. Facial angiofibromas affect most patients with tuberous sclerosis complex. They tend to progress, can cause recurrent bleeding and facial disfigurement, and have significant psychological effects. We reviewed the effectiveness and safety of topical sirolimus ointment 0.1%. We also assess...
Autores principales: | Amin, S., Lux, A., Khan, A., O'Callaghan, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705889/ https://www.ncbi.nlm.nih.gov/pubmed/29270462 http://dx.doi.org/10.1155/2017/8404378 |
Ejemplares similares
-
Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015) -
Facial Angiofibromas and Periungual Fibromas in Tuberous Sclerosis
por: Tsujimoto, Hiraku, et al.
Publicado: (2017) -
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017) -
Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
por: Okanishi, Tohru, et al.
Publicado: (2020) -
Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
por: Hatano, Takashi, et al.
Publicado: (2020)